Myelodysplastic Syndrome (MDS) cells present genetic instability and dysregulation of the gene C30RF9, which was isolated from an MDS cDNA library and codes for a putative protein. We studied the expression of C30RF9 in MDS syndromes to contribute to the understanding of the pathophysiology of MDS. One hundred and thirty-one patients and 35 healthy controls were involved in our study. Bone marrow aspirates and isolated CD34+ cells were used. Gene expression was estimated by quantitative PCR. C30RF9 was found to be down-regulated in patients with CMML compared to the controls (p<0.01). There was no difference between RARS and the controls (p=0.1), while increased expression was found in RA, RAEB and RAEB-T (p< 0.01 for all). No mutations or polymorphism were detected in our population. CD34+ cells expressed higher levels of C30RF9 (p<O.OI) in patients. The gene expression was correlated to the percentage of+ cells in RAEB and RAEB-T (r= 0.64). The altered C30RF9 expression was possibly due to different gene regulation in these patients and/or to the increased CD34+ cells.
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haemopoietic disorders, characterized by ineffective hemopoiesis, and increased probability of transformation to acute leukaemia (1) . The incidence in the general population is 2.1-12.6 per 100,000 per year, while in the elderly population over 70 years of age it is 50 per 100,000 per year, and over 80 years of age it is 89 per 100,000 per year (2) (3) . MDS account for 1-3% of child neoplasias (4) (5) . Their prognosis is poor and only 6% exceeds 7 years of survival (4) .
The disease progress takes place in two distinguished phases (3-7): a) an early phase, in which the risk of transformation to acute leukaemia is low; and b) a late phase where the risk of transformation to acute leukaemia is high (IPSS score 1.5->2.5) (4). In MDS the neoplastic transformation takes place in the stem cell and, contrary to the acute leukaemias, the neoplastic clone retains the ability of maturation and differentiation. During disease progress the MDS clone gains a growth advantage over the normal cells and, finally, the normal hemopoiesis is totally suppressed.
The MDS cells progressively show genetic instability, cytogenetic abnormalities and molecular mutations that lead to reduction of apoptosis and differentiation of stem cells, favouring uncontrolled proliferation and the leukaemic transformation of cells (3) (4) 7) . In addition, modification of the bone marrow microenvironment is observed as well as immune abnormalities (3) .
The gene C30RF9 was isolated from a eDNA library of bone marrow of a patient suffering from MDS (8) and it codes for a putative protein called X 010 of 46.189 Da. In humans it is located on chromosome 3gB.33. The XOIO is contained in microsomes and has homology to cell membrane proteins but its precise action is not known (9) (10) . The protein is expressed in stem cells, in peripheral blood lymphocytes and in 12 other adult tissues, with the liver showing the highest expression. It is shown, that the expression of protein XOIO (the hCLP 46) is higher in rapidly growing cells (8) . However, it is also expressed in some tissues with low mitotic index (8, 11) .
Because of its homologies and its position, the protein seems to playa role in the regulation of stem cell compartments as well as cell differentiation, but it may have multiple and different functions in various tissues (8) . The XO 10 protein contains capsule-associated protein-IO domain (CAP-lO), a domain with homology to endoplasmic reticulum (ER) proteins and a hydrophobic signal peptide (8) . The ER proteins help in the retention of proteins to the endoplasmic reticulum (ER). Taking into account the protein homologies, it is assumed that it is an enzyme, which modifies the polysaccharides (lipolysaccharides modifying enzyme) (9, 12) .
The lipolysaccharides are molecules attached to membrane proteins with various functions and strong antigenic activity. The modification of these molecules may lead to a change of cell antigenicity and abnormal immune reactions to humans (12) . We studied the expression of this gene in MDS patients vs normal counterparts because it was first isolated from a eDNA library of an MDS patient. Different expression in these 2 groups may mean involvement in the pathophysiology of MDS. This is a part of a wider project in which we search for differential gene expression in MDS patients in order to contribute to the understanding of the pathophysiology of MDS.
MATERIALS AND METHODS

Patients
One hundred and thirty-one patients suffering from primary MDS, 59 women and 72 men aged 33-85 years (median 69), as well as 35 healthy volunteers, 17 women and 18 men aged 33-85 (median 71), were included in the study. Patients with secondary MDS were not involved in the study. Classification of patients into subgroups was based on the WHO criteria (6) . The clinical and laboratory characteristics of patients are shown in Table I and of the  healthy individuals in Table II . Both the patients and controls gave their informed consent and the study was approved by the Ethical Committee of our Hospital.
Bone marrow and peripheral blood samples
Whole blood was collected in EDTA, and centrifuged at 3500 g at 4°C. We isolated the buffy coat and immediately placed it in dry ice and transported it to the laboratory within one hour. Another sample was processed for peripheral blood mononuclear cell (PBMC) isolation on Iymphoprep. Bone marrow aspirates were also used for mononuclear cell (BMMC) isolation and nucleic acid extraction. RNA and DNA were extracted using standard techniques (13) (14) (15) (16) (17) , and the nucleic acids were stored at -80°C and +4°C, respectively.
Isolation ofCD34+ cells
CD34+ cells were isolated from PBMC and BMMC using magnetic beads. The CD34+ (clone 571) conjugated with magnetic beads used was obtained by Miltenyi Biotech (Bergisch Glandbach, Germany) with the MiniMacs system (Miltenyii Biotec Inc Auburn, CA, USA) according to the manufacturers' instructions. Purity was checked by flow cytometry and it was >95%.
Karyotyping
We isolated peripheral blood mononuclear cells (PBMC) and bone marrow mononuclear cells (BMMC) using the gradient centrifugation method on Ficoll-Hypaque. The cells were cultured in RPMI-I640 complete medium with IL-2 and phytohemaglutamin (PHA) or phorbol ester as (TPA/PMA). Colchicine was used as a metaphase inhibitor. The examination of chromosomal abnormalities was made using G-banding. This technique is based on the use of trypsin and Leishman staining for better discrimination of G-bands. The bands reflect the structure and function of chromosomes (18) .
Reverse transcription-polymerase chain reaction( RT-PCR)
RT-PCR was performed in RNA samples from patients and healthy individuals using the superscript ™ one step ™ RT-PCR system by GIBCO-BRL (Gaithesburge, MD, USA) according to the manufacturer's instructions (19) .~-actin was used as housekeeping gene for RT-PCR experiments. For quantification of PCR products, electrophoresis was performed on 2% agarose gel (Ultrapure, BRL), elution of the cDNA bands and spectrophotometric measurement (Quant-it ds DNA HS, Invitrogen U.S., Carlsbad, California).
The primers, used for amplification of~-actin were the following: ActF: 5 '-cca-gcc-atg-tag-gtt-gct-atc-ca-3' and ActR: 5 '<cag-ccg-tgg-cca-tct-ctt-gc-B', that give a product of 290bp corresponding to the 3' -UTR of the [3-actin mRNA. For C30RF9 amplification the following primers were used: C30RF9-F: 5'-ccg-cca-gaa-gga-gtcagg-ttc-aaa-J' and C30RF9-R: 5' -ccc-tag-ctt-ccg-tct-gactac-ctc-3' that gives a product of 190 bp corresponding to the translated region of mRNA in order to avoid false positive products from possible DNA contamination. The product corresponds to a region common for the 2 transcripts of the C30RF9 gene (19) .
The conditions used were: initial denaturation at 94°C for 2 min, then 30 cycles with: denaturation at 94°for 30 sec, annealing at 48°C for 30 sec, extension at 65°C for 30 sec. A final extension was made at 72°C for 10 min. The Peltier Gradient Thermal Cycler (Biorad Ltd Corston Bath UK) was used (20) .
Quantitative real time PCR (Q-PCR)
Real time PCR was performed on the Rotorgene RG-3000 (RCorbett research) using the Invitrogen CYBR®Green Universal kit according to the manufacturer's instructions. The primers used were the same as in RT-PCR for the C30RF9 gene and~-actin gene.~-actin was used as housekeeping gene.
DNA sequencing
The exons of gene C30RF9 were amplified using flanking primers, and the product was processed for direct sequencing on ABI PRISM (Applied Biosystems). The Big Dye terminator kit v3.1 by Applied Biosystems (USA) was used according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was made using SPSS v15. The results are expressed as mean value±SD or median (range) unless otherwise stated. To check the normality of distribution in various parameters Shapiro-Wilk test was used. To find statistical differences between parametric values the T test was used, and for non-parametric variables the Mann-Whitney test was used (with Bonferonni's correction for multiple comparisons).
RESULTS
Chromosomal abnormalities
Of the 131 patients, 46 had normal karyotype, 16 had trisomy 8, 8 had del Sq, 12 had de120, 11 had monosomy 7, and the remaining had complex chromosomal abnormalities (data not shown). There was no difference in C30RF9 expression between those who had chromosomal abnormalities and those who had not.
Expression analysis ofC30RF
The RT-PCR products of some experiments on agarose gel are shown in Figs. 1 and 2 . The ratio of C30RF9!J3-actin RNA copies in patients divided by the ratio of C30RF9/~-actin RNA copies in the normal individuals is shown in Table III for and in RA, RAEB, RAEB-T it was significantly higher than the controls (p<O.OI for all). The highest expression was observed in RAEB (250%±30%).
In isolated CD34+ cells of patients with MDS the expression was higher than that of normal CD34+ cells (p<O.OI), in all MDS categories. The C30RF9 expression in the patients with RAEB and RAEB-t correlated with the percentage CD34+ cells in the peripheral blood (r=O.64), but this was not true for the remaining MDS patients. Although the differences were as described above, 6 patients with RA and 1 patient with CMML did not have detectable values of C30RF9 cDNA, and 2 patients with RA had very low amounts of C30RF9 cDNA «I %). This was not observed in any controls, where the variability in C30RF9 expression was much smaller. Spectrophotometric quantification of the eluted cDNA bands from the reverse transcriptase PCR gave comparable results to the measurements of the real time quantitative PCR.
Analysis ofthe DNA sequence ofgene C30RF9
Mutation analysis performed in C30RF9 exons by direct sequencing did not reveal any mutation or polymorphism in these patients. 
DISCUSSION
We studied the expression of C30RF 9 gene in patients with MDS in an effort to study mechanisms that can be involved in the pathophysiology, the course and outcome of the syndrome. The C30RF9 codes for a putative protein (hCLP-46) of 392 amino acids which contains a hydrophobic signal peptide in the N-tenninal region and does not contain a transmembrane domain. The presence of the signal peptide suggests the entrance of the protein into the secretion route (8) . The C-tenninal region contains an endoplasmatic reticulum retention peptide (ER retention motif). The ER proteins which contain such domains are prevented from secretion by a selection system which recognizes this peptide receptor, and immobilizes the proteins in the ER or selects them in a following stage and returns them to the normal position. The hCLP-46 is located in microsomes and is soluble (8) . The accurate function of hCLP-46 is not known. The fact that it contains ER-retention motif suggests that it participates in the production, the trafficking and regulation of many proteins adherent to the ER.
The deregulation of this system of proteins probably causes abnormal functions of the cell which are particularly obvious in the cells of MDS clone. It is known that hCLP-46 inhibits the TGFrelated regulation of p 15 function that leads to the loss of growth control of leukaemic cells. But this mechanism of action of hCLP-46 has not been well studied.
It is known, that protein hCLP-46 is highly expressed in the CD34+ cells. Transfection of COS-7 cells with plasmid, expressing hCLP-46, led to the acceleration of proliferation of COS -7 cells (8) . Over-expression of C30RF9 in MDS cells may suggest an increased proliferation rate of these cells, which means a proliferation advantage over normal hemopoietic cells. It is known that MDS cells have a higher proliferation rate in high risk MDS. The exact mechanism of how this gene is involved in cell proliferation is not known. It is also not known why in CMML this gene is downregulated, although the proliferation rate of CMML cells is also higher than normal and the number of CD34+ cells is also increased. Perhaps other agents are involved in the regulation of this gene as well as cell proliferation. Alternatively, the presence of the monocytic population may be causing downregulation of the C30rf9 gene in the CD34 compartment.
It is also difficult to explain the increased expression in RA where the CD34+ cells do not differ significantly from the controls. But, the fact that the expression in RARS did not differ from controls is consistent with the normal content of CD34+ cells in RARS. In addition, the very low expression in some cases means that a different regulation of the gene may exist in a genetic or epigenetic level in these patients. It is also equally important to bear in mind that levels of gene expression do not always reflect protein production. The interesting findings from the differential gene expression of the C30RF9 gene would be enlightened if we could determine the levels of protein expression, e.g. in a Western blot approach. This limitation could be overcome in the future if a detecting antibody becomes available.
The ER proteins are important in the cell because, many of them are involved in the function and trafficking of other proteins. Because of this, the dysregulation of C30RF9 expression may lead to many abnormal functions in MDS cells. The predictive value of hCLP-46 in disease course and outcome would be of clinical interest and such a prospective study is the continuation of our study.
